GlassScriptPhysician profile
Hanni Salih
NPI 1245594639
$12,154.36
in general payments reported to CMS, 2019-2025
69 companies · $1,138 in 2025
The $1,138 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,390 · 2020: $1,657 · 2021: $1,430 · 2022: $1,664 · 2023: $692 · 2024: $1,183 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976 · Education: $37.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.04 |
| Education | $37.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,612.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $710.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $635.10 | 2019-2025 | Calquence, Enhertu |
| Astellas Pharma US INC | $607.65 | 2019-2025 | Vyloy, Xospata |
| E.R. Squibb & Sons, L.L.C. | $506.70 | 2019-2025 | Opdualag |
| Celgene Corporation | $441.49 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $441.29 | 2019-2025 | |
| Janssen Biotech, INC. | $419.84 | 2019-2024 | Tecvayli, Akeega, Erleada |
| Genentech USA, INC. | $371.55 | 2019-2025 | Tecentriq, Tecentriq Hybreza, Rituxan |
| Regeneron Healthcare Solutions, INC. | $325.14 | 2021-2025 | Libtayo |
| Incyte Corporation | $312.91 | 2019-2022 | |
| Daiichi Sankyo INC. | $301.51 | 2019-2024 | Enhertu, Vanflyta |
| Galvanize Therapeutics, INC | $265.84 | 2023-2025 | Aliya System |
| Amgen INC. | $261.37 | 2020-2022 | |
| Seagen INC. | $248.57 | 2019-2023 | Adcetris |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanni Salih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.